Ildong Pharmaceutical Co., Ltd. (249420.KS)
KRW 11350.0
(-5.42%)
KRW 11350.0
(-5.42%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 14.82 Billion KRW | -75.04% |
| 2022 | 59.38 Billion KRW | -35.25% |
| 2021 | 91.72 Billion KRW | 23.11% |
| 2020 | 74.49 Billion KRW | 35.0% |
| 2019 | 55.18 Billion KRW | 53.29% |
| 2018 | 36 Billion KRW | -20.0% |
| 2017 | 45 Billion KRW | -29.69% |
| 2016 | 64 Billion KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 42.5 Billion KRW | 186.73% |
| 2024 Q2 | 30 Billion KRW | -29.43% |
| 2023 Q4 | 14.82 Billion KRW | -53.62% |
| 2023 FY | 14.82 Billion KRW | -75.04% |
| 2023 Q2 | 45.91 Billion KRW | -1.03% |
| 2023 Q1 | 46.38 Billion KRW | -21.89% |
| 2023 Q3 | 31.96 Billion KRW | -30.38% |
| 2022 Q1 | 72.88 Billion KRW | -20.53% |
| 2022 Q4 | 59.38 Billion KRW | 19.57% |
| 2022 Q3 | 49.66 Billion KRW | -32.45% |
| 2022 Q2 | 73.53 Billion KRW | 0.88% |
| 2022 FY | 59.38 Billion KRW | -35.25% |
| 2021 Q2 | 123.71 Billion KRW | -7.0% |
| 2021 Q3 | 110.21 Billion KRW | -10.91% |
| 2021 Q4 | 91.72 Billion KRW | -16.78% |
| 2021 FY | 91.72 Billion KRW | 23.11% |
| 2021 Q1 | 133.03 Billion KRW | 78.57% |
| 2020 Q1 | 59.44 Billion KRW | 7.71% |
| 2020 Q2 | 57.87 Billion KRW | -2.63% |
| 2020 FY | 74.49 Billion KRW | 35.0% |
| 2020 Q4 | 74.49 Billion KRW | 3.94% |
| 2020 Q3 | 71.67 Billion KRW | 23.84% |
| 2019 Q4 | 55.18 Billion KRW | -13.83% |
| 2019 Q3 | 64.04 Billion KRW | 0.28% |
| 2019 Q2 | 63.86 Billion KRW | -4.35% |
| 2019 Q1 | 66.76 Billion KRW | 85.46% |
| 2019 FY | 55.18 Billion KRW | 53.29% |
| 2018 Q2 | 44 Billion KRW | -3.3% |
| 2018 Q4 | 36 Billion KRW | 10.77% |
| 2018 Q1 | 45.5 Billion KRW | 1.11% |
| 2018 Q3 | 32.5 Billion KRW | -26.14% |
| 2018 FY | 36 Billion KRW | -20.0% |
| 2017 Q3 | 61.5 Billion KRW | 4.24% |
| 2017 Q1 | 60.5 Billion KRW | -5.47% |
| 2017 FY | 45 Billion KRW | -29.69% |
| 2017 Q2 | 59 Billion KRW | -2.48% |
| 2017 Q4 | 45 Billion KRW | -26.83% |
| 2016 FY | 64 Billion KRW | 0.0% |
| 2016 Q4 | 64 Billion KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -8.689% |
| Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 92.663% |
| Ildong Holdings Co., Ltd. | 29.87 Billion KRW | 50.379% |
| HANDOK Inc. | 123.78 Billion KRW | 88.023% |
| Kukje Pharma Co., Ltd. | 475.74 Million KRW | -3016.217% |
| Yuhan Corporation | 60.23 Billion KRW | 75.387% |
| Dong-A ST Co., Ltd. | 161.99 Billion KRW | 90.848% |
| SAMSUNG PHARM. Co., LTD. | 101.81 Million KRW | -14460.499% |
| Hanmi Pharm. Co., Ltd. | 82.02 Billion KRW | 81.927% |
| Hanall Biopharma Co.,Ltd | 590.3 Million KRW | -2411.426% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -145.044% |
| Dong Sung Bio Pharm.Co.,Ltd. | 18.52 Billion KRW | 19.961% |
| MYUNGMOON Pharm co.,Ltd | 12.58 Billion KRW | -17.808% |
| Hana Pharm Co., Ltd. | 1.59 Billion KRW | -827.242% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -8.689% |
| Ilsung Pharmaceuticals Co., Ltd. | 119.67 Million KRW | -12287.514% |
| REYON Pharmaceutical Co., Ltd. | 121 Billion KRW | 87.748% |
| Aprogen pharmaceuticals,Inc. | 32 Billion KRW | 53.671% |
| JW Holdings Corporation | 20.65 Billion KRW | 28.233% |
| Chong Kun Dang Pharmaceutical Corp. | 30 Billion KRW | 50.583% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 50.583% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -6670.693% |
| Hyundai Pharmaceutical Co., Ltd. | 580.64 Million KRW | -2453.221% |
| Samil Pharmaceutical Co.,Ltd | 49.56 Billion KRW | 70.092% |
| Jeil Pharmaceutical Co.,Ltd | 4.45 Billion KRW | -233.0% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -8.689% |
| Kwang Dong Pharmaceutical Co., Ltd. | 19.02 Billion KRW | 22.086% |
| Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | 84.13% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 50.583% |
| Yuhan Corporation | 60.23 Billion KRW | 75.387% |
| Jeil Pharma Holdings Inc | 10.5 Billion KRW | -41.192% |
| Yungjin Pharm. Co., Ltd. | 40.37 Billion KRW | 63.284% |
| Suheung Co., Ltd. | 74 Billion KRW | 79.968% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 50.583% |
| Samjin Pharmaceuticals Co., Ltd. | 4.16 Billion KRW | -255.807% |
| Korea United Pharm Inc. | 10.96 Billion KRW | -35.235% |
| CKD Bio Corp. | 69.43 Billion KRW | 78.648% |
| Daewon Pharmaceutical Co., Ltd. | 34.57 Billion KRW | 57.121% |
| Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | 8.076% |
| Whan In Pharm Co.,Ltd. | 307.05 Million KRW | -4728.164% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -6670.693% |
| Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | 79.442% |
| Boryung Corporation | 151.7 Billion KRW | 90.228% |
| Bukwang Pharmaceutical Co., Ltd. | 78.52 Billion KRW | 81.12% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -145.044% |
| JW Lifescience Corporation | 168 Million KRW | -8724.511% |